Drug Profile
Research programme: anti-infectives - Redx Pharma
Latest Information Update: 28 Oct 2018
Price :
$50
*
At a glance
- Originator Redx Pharma
- Class Small molecules
- Mechanism of Action DNA gyrase modulators; Immunomodulators; Neuraminidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Bacterial infections; Gram-negative infections; Gram-positive infections; Hepatitis B; Influenza virus infections
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for research development in Gram-negative-infections in United Kingdom
- 28 Oct 2018 No recent reports of development identified for research development in Gram-positive-infections in United Kingdom
- 28 Oct 2018 No recent reports of development identified for research development in Hepatitis-B in United Kingdom